SCHEMBL8550657

SCHEMBL8550657

OCc1csc(C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.34
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24344881 0.83 KDM4E (0.32)
SCHEMBL8403255 0.80 MCHR1 (0.32)
SCHEMBL15898867 0.78
SCHEMBL128532 0.78
SCHEMBL10674149 0.77 MAPT (0.31) ACHE
SCHEMBL3935172 0.71
SCHEMBL24346637 0.70 S1PR1 (0.32)
SCHEMBL15110866 0.70
SCHEMBL1244370 0.70 DAO (0.30) KIF11
SCHEMBL5861836 0.69 PSEN1 (0.41) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS PHENEX-FXR GMBH (DE) 2020-04-16 US disclosed
EP-3609880-A1 LIVER X RECEPTORS (LXR) MODULATORS Phenex-FXR GmbH (DE) 2020-02-19 EP disclosed
CN-110546144-A Liver X Receptor (LXR) modulators PHENEX FXR GMBH 2019-12-06 CN disclosed
WO-2018188795-A1 LIVER X RECEPTORS (LXR) MODULATORS PHENEX-FXR GMBH (DE) 2018-10-18 WO disclosed
US-9365540-B2 Benzimidazole derivatives as MCH receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
EP-3019487-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-05-18 EP disclosed
US-9199963-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-01 US disclosed
WO-2015005489-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-15 WO disclosed
EP-2802571-A1 BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2014-11-19 EP disclosed
WO-2013105676-A1 BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-18 WO disclosed
EP-0693490-B1 2-Phenoxy-6-thienylmethyloxypyridine derivative, process for producing the same, and herbicidal composition KUREHA CHEMICAL IND CO LTD (JP) 1998-09-09 EP disclosed
US-5624942-A 2-phenoxy-6-thienylmethyloxypyridine derivative and herbicidal composition containing same KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1997-04-29 US disclosed
EP-0693490-A1 2-Phenoxy-6-thienylmethyloxypyridine derivative, process for producing the same, and herbicidal composition KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS NR1H2, NR1H3, NR1H4 KIF11 4435/4885ACHE 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.